<?xml version='1.0' encoding='utf-8'?>
<document id="29880631"><sentence text="Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey." /><sentence text="We aim to establish an in vivo preclinical model to enable simultaneous assessment of inhibition potential of an investigational drug on clinically relevant drug transporters, organic anion-transporting polypeptide (OATP)1B, breast cancer resistance protein (BCRP), P-glycoprotein (P-gp), and organic anion transporter (OAT)3" /><sentence text=" Pharmacokinetics of substrate cocktail consisting of pitavastatin (OATP1B substrate), rosuvastatin (OATP1B/BCRP/OAT3), sulfasalazine (BCRP), and talinolol (P-gp) were obtained in cynomolgus monkey-alone or in combination with transporter inhibitors"><entity charOffset="54-66" id="DDI-PubMed.29880631.s3.e0" text="pitavastatin" /><entity charOffset="68-74" id="DDI-PubMed.29880631.s3.e1" text="OATP1B" /><entity charOffset="87-99" id="DDI-PubMed.29880631.s3.e2" text="rosuvastatin" /><entity charOffset="101-107" id="DDI-PubMed.29880631.s3.e3" text="OATP1B" /><entity charOffset="120-133" id="DDI-PubMed.29880631.s3.e4" text="sulfasalazine" /><entity charOffset="135-139" id="DDI-PubMed.29880631.s3.e5" text="BCRP" /><entity charOffset="146-155" id="DDI-PubMed.29880631.s3.e6" text="talinolol" /><entity charOffset="108-116" id="DDI-PubMed.29880631.s3.e7" text="BCRP" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e0" e2="DDI-PubMed.29880631.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e0" e2="DDI-PubMed.29880631.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e0" e2="DDI-PubMed.29880631.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e0" e2="DDI-PubMed.29880631.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e0" e2="DDI-PubMed.29880631.s3.e7" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e0" e2="DDI-PubMed.29880631.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e0" e2="DDI-PubMed.29880631.s3.e5" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e0" e2="DDI-PubMed.29880631.s3.e6" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e1" e2="DDI-PubMed.29880631.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e1" e2="DDI-PubMed.29880631.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e1" e2="DDI-PubMed.29880631.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e1" e2="DDI-PubMed.29880631.s3.e7" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e1" e2="DDI-PubMed.29880631.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e1" e2="DDI-PubMed.29880631.s3.e5" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e1" e2="DDI-PubMed.29880631.s3.e6" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e2" e2="DDI-PubMed.29880631.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e2" e2="DDI-PubMed.29880631.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e2" e2="DDI-PubMed.29880631.s3.e7" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e2" e2="DDI-PubMed.29880631.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e2" e2="DDI-PubMed.29880631.s3.e5" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e2" e2="DDI-PubMed.29880631.s3.e6" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e3" e2="DDI-PubMed.29880631.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e3" e2="DDI-PubMed.29880631.s3.e7" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e3" e2="DDI-PubMed.29880631.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e3" e2="DDI-PubMed.29880631.s3.e5" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e3" e2="DDI-PubMed.29880631.s3.e6" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e7" e2="DDI-PubMed.29880631.s3.e7" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e7" e2="DDI-PubMed.29880631.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e7" e2="DDI-PubMed.29880631.s3.e5" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e7" e2="DDI-PubMed.29880631.s3.e6" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e4" e2="DDI-PubMed.29880631.s3.e4" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e4" e2="DDI-PubMed.29880631.s3.e5" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e4" e2="DDI-PubMed.29880631.s3.e6" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e5" e2="DDI-PubMed.29880631.s3.e5" /><pair ddi="false" e1="DDI-PubMed.29880631.s3.e5" e2="DDI-PubMed.29880631.s3.e6" /></sentence><sentence text=" Single-dose rifampicin (30 mg/kg) significantly (P &lt; 0"><entity charOffset="13-23" id="DDI-PubMed.29880631.s4.e0" text="rifampicin" /></sentence><sentence text="01) increased the plasma exposure of all four drugs, with a marked effect on pitavastatin and rosuvastatin [area under the plasma concentration-time curve (AUC) ratio ∼21-39]"><entity charOffset="77-89" id="DDI-PubMed.29880631.s5.e0" text="pitavastatin" /><entity charOffset="94-106" id="DDI-PubMed.29880631.s5.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.29880631.s5.e0" e2="DDI-PubMed.29880631.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29880631.s5.e0" e2="DDI-PubMed.29880631.s5.e1" /></sentence><sentence text=" Elacridar, BCRP/P-gp inhibitor, increased the AUC of sulfasalazine, talinolol, as well as rosuvastatin and pitavastatin"><entity charOffset="54-67" id="DDI-PubMed.29880631.s6.e0" text="sulfasalazine" /><entity charOffset="69-78" id="DDI-PubMed.29880631.s6.e1" text="talinolol" /><entity charOffset="91-103" id="DDI-PubMed.29880631.s6.e2" text="rosuvastatin" /><entity charOffset="108-120" id="DDI-PubMed.29880631.s6.e3" text="pitavastatin" /><entity charOffset="12-23" id="DDI-PubMed.29880631.s6.e4" text="BCRP" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e4" e2="DDI-PubMed.29880631.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e4" e2="DDI-PubMed.29880631.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e4" e2="DDI-PubMed.29880631.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e4" e2="DDI-PubMed.29880631.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e4" e2="DDI-PubMed.29880631.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e0" e2="DDI-PubMed.29880631.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e0" e2="DDI-PubMed.29880631.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e0" e2="DDI-PubMed.29880631.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e0" e2="DDI-PubMed.29880631.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e1" e2="DDI-PubMed.29880631.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e1" e2="DDI-PubMed.29880631.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e1" e2="DDI-PubMed.29880631.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e2" e2="DDI-PubMed.29880631.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s6.e2" e2="DDI-PubMed.29880631.s6.e3" /></sentence><sentence text=" An OAT1/3 inhibitor (probenecid) significantly (P &lt; 0" /><sentence text="05) impacted the renal clearance of rosuvastatin (∼8-fold)"><entity charOffset="36-48" id="DDI-PubMed.29880631.s8.e0" text="rosuvastatin" /><entity charOffset="50-57" id="DDI-PubMed.29880631.s8.e1" text="∼8-fold" /><pair ddi="false" e1="DDI-PubMed.29880631.s8.e0" e2="DDI-PubMed.29880631.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29880631.s8.e0" e2="DDI-PubMed.29880631.s8.e1" /></sentence><sentence text=" In vitro, rifampicin (10 µM) inhibited uptake of pitavastatin, rosuvastatin, and sulfasalazine by monkey and human primary hepatocytes"><entity charOffset="11-21" id="DDI-PubMed.29880631.s9.e0" text="rifampicin" /><entity charOffset="50-62" id="DDI-PubMed.29880631.s9.e1" text="pitavastatin" /><entity charOffset="64-76" id="DDI-PubMed.29880631.s9.e2" text="rosuvastatin" /><entity charOffset="82-95" id="DDI-PubMed.29880631.s9.e3" text="sulfasalazine" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e0" e2="DDI-PubMed.29880631.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e0" e2="DDI-PubMed.29880631.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e0" e2="DDI-PubMed.29880631.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e0" e2="DDI-PubMed.29880631.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e1" e2="DDI-PubMed.29880631.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e1" e2="DDI-PubMed.29880631.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e1" e2="DDI-PubMed.29880631.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e2" e2="DDI-PubMed.29880631.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s9.e2" e2="DDI-PubMed.29880631.s9.e3" /></sentence><sentence text=" Transport studies using membrane vesicles suggested that all probe substrates, except talinolol, are transported by cynoBCRP, whereas talinolol is a cynoP-gp substrate"><entity charOffset="87-96" id="DDI-PubMed.29880631.s10.e0" text="talinolol" /><entity charOffset="135-144" id="DDI-PubMed.29880631.s10.e1" text="talinolol" /><entity charOffset="121-129" id="DDI-PubMed.29880631.s10.e2" text="BCRP" /><pair ddi="false" e1="DDI-PubMed.29880631.s10.e0" e2="DDI-PubMed.29880631.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29880631.s10.e0" e2="DDI-PubMed.29880631.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s10.e0" e2="DDI-PubMed.29880631.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29880631.s10.e2" e2="DDI-PubMed.29880631.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29880631.s10.e2" e2="DDI-PubMed.29880631.s10.e1" /></sentence><sentence text=" Elacridar and rifampicin inhibited both cynoBCRP and cynoP-gp in vitro, indicating potential for in vivo intestinal efflux inhibition"><entity charOffset="15-25" id="DDI-PubMed.29880631.s11.e0" text="rifampicin" /><entity charOffset="45-54" id="DDI-PubMed.29880631.s11.e1" text="BCRP" /><pair ddi="false" e1="DDI-PubMed.29880631.s11.e0" e2="DDI-PubMed.29880631.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29880631.s11.e0" e2="DDI-PubMed.29880631.s11.e1" /></sentence><sentence text=" In conclusion, a probe substrate cocktail was validated to simultaneously evaluate perpetrator impact on multiple clinically relevant transporters using the cynomolgus monkey" /><sentence text=" The results support the use of the cynomolgus monkey as a model that could enable drug-drug interaction risk assessment, before advancing a new molecular entity into clinical development, as well as providing mechanistic insights on transporter-mediated interactions" /><sentence text="" /></document>